Gen-Probe (San Diego, CA, USA) has acquired GTI Diagnostics (Waukesha, WI, USA) for USD 53 million in cash. The acquisition strengthens Gen-Probe's transplant diagnostics business, providing new growth opportunities in blood bank and specialty coagulation markets.
GTI Diagnostics is a privately held specialty diagnostics company focused on the transplantation, blood bank, and specialty coagulation markets. Gen-Probe acquired GTI from the Riverside Company, a global private equity firm, and from individual investors who include the company's founders and management.
GTI develops and manufactures the human leukocyte antigen (HLA) antibody detection products sold by Gen-Probe under its Lifecodes brand. GTI also commercializes a number of other HLA-related testing products, including serological typing trays, enzyme immunoassays (EIAs), and a range of molecular typing products for donor-recipient matching and patient monitoring.
In the specialty coagulation market, GTI sells immunoassay products that measure a patient's immune response to heparin and Factor VIII therapies. The blood bank product line includes immunoassay products that measure antibodies developed against transfused platelets.
Gen-Probe Inc. develops, manufactures, and markets rapid, accurate, and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility.